[
  {
    "ts": null,
    "headline": "Biogen Begins Phase III Felzartamab Study for Third Kidney Disease",
    "summary": "BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.",
    "url": "https://finnhub.io/api/news?id=065d3bd2b2359a15da5b3d0762f8a615d917683cc0f0ac3781c6d23a179a7c2f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751381400,
      "headline": "Biogen Begins Phase III Felzartamab Study for Third Kidney Disease",
      "id": 135694665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.",
      "url": "https://finnhub.io/api/news?id=065d3bd2b2359a15da5b3d0762f8a615d917683cc0f0ac3781c6d23a179a7c2f"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons BIIB is Risky and 1 Stock to Buy Instead",
    "summary": "Over the past six months, Biogen’s stock price fell to $125.58. Shareholders have lost 16.3% of their capital, which is disappointing considering the S&P 500 has climbed by 5.7%. This might have investors contemplating their next move.",
    "url": "https://finnhub.io/api/news?id=eddb1804046442fce8fc81ada6ac4ce666824a7b09ee5f5330ba099ad06954c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751342606,
      "headline": "3 Reasons BIIB is Risky and 1 Stock to Buy Instead",
      "id": 135694666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Over the past six months, Biogen’s stock price fell to $125.58. Shareholders have lost 16.3% of their capital, which is disappointing considering the S&P 500 has climbed by 5.7%. This might have investors contemplating their next move.",
      "url": "https://finnhub.io/api/news?id=eddb1804046442fce8fc81ada6ac4ce666824a7b09ee5f5330ba099ad06954c0"
    }
  }
]